WO1991001712A1 - Preparation pour aerosol en mousse - Google Patents
Preparation pour aerosol en mousse Download PDFInfo
- Publication number
- WO1991001712A1 WO1991001712A1 PCT/JP1990/000944 JP9000944W WO9101712A1 WO 1991001712 A1 WO1991001712 A1 WO 1991001712A1 JP 9000944 W JP9000944 W JP 9000944W WO 9101712 A1 WO9101712 A1 WO 9101712A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- foam
- volume
- gas
- cracking
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/046—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/24—Thermal properties
- A61K2800/244—Endothermic; Cooling; Cooling sensation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Definitions
- the present invention relates to a foam aerosol formulation used as a base for cosmetics, quasi-drugs, and pharmaceuticals, and as cosmetics, quasi-drugs, and pharmaceuticals. More specifically, CL is a type of foam aerosol formulation that forms a foam when applied to the skin and makes a crackling sound when rubbed with the palm. It relates to a packing form preparation. Background art
- the prior art of cracking foam preparations includes JP-B-45-32053, JP-A-63-141910, JP-A-63-U1917, and JP-A-63-141918.
- emulsifiers and propellants all of them were polyoxyethylene polyoxypropylene alkyl ethers as emulsifiers.
- dichlorotetrafluorophenol (Fron 114) is used as a propellant.
- the reason for adopting such a combination is that other combinations do not have a good bubble state or cracking sound, and there are no restrictions on the use of the front 114 in the past. Power.
- n-butane having a high boiling point as a propellant, does not use any fluorinated gas, and is a suitable emulsifier for chlorofluorocarbon 114. It does not use any of the above-mentioned technologies and is completely different from the prior art.
- the power that can be manufactured In particular, in the case where the active ingredients such as £ -mento nore, glycolic acid salicylate, methyl salicylate, etc. are blended, the emulsification occurs because the oil phase component increases. It was not possible to make a formulation that had both the sound and the cracking sound.
- the purpose of the present invention is to provide a cracking foam formulation having both a foam and a cracking sound without using Fluorocarbon 11 as a propellant. It must be manufactured. Disclosure of the invention
- the present inventors have conducted various studies on cracking foam formulations using liquefied petroleum gas or the like as a propellant. As a result, the boiling point of the liquefied petroleum gas component was determined. High n-butane-based gas is indispensable for producing cracking foam products, and a certain amount of surfactant must be added to it. As a result, the present inventors have found that a preparation having good foaming and good cracking sound can be obtained, and thus completed the present invention.
- the present invention relates to a surfactant Q. 1 to 5% by weight / vol.% Lower alcohol and no or glycols 0.05 to 10% by weight, vol.
- a foam aerosol formulation consisting of ⁇ 25 wt% by volume and n-butane gas from 60 to 95 wt%, and surfactant 0.1 to 5 wt% by volume; Low-grade alcohol and / or glycols 0.05 to 10% by weight Z volume%, water 3 to 25% by weight volume and n — butane gas 60 to 95% by weight
- surfactant examples include polyoxyethylene alkyl ether ethers and sulfates of polyoxyethylene alkyl ether. Is acetate and Z or poly Sulfuric acid or acetic acid salt of styrene alkyl ether ether is preferably used.
- polyoxyethylene alkyl ether ethers include polyoxyethylene nonyl ether, tenor, and polyoxyethylene. Examples include cutenyl ethers, and particularly preferred are polyoxyethylenile ethers having an HLB of 10 to 16.
- Examples of the sulfate or acetate of polyoxyethylene alkyl ether and the sulfate or acetate of polyoxyethylene alkyl ether examples include sodium polyoxyethylene laurel ether sulfate, sodium polyoxyethylene benzoyl ether, sodium sodium polyacetate, and polyoxyethylene.
- Ethanol and Isopropanol are low-level vinyl records. But ethanol is preferred. Glyco-monoles include propylene glycol, 1,3-butanediol, 3—methyl-1,3—butanediol. , Propylene glycol, tripropylene glycol, glycerin, polyoxyethylene polyoxypropylene Calls, Polyethylene calls and the like. These lower alcohols or glycols may be used alone or in combination of two or more ( ⁇ ( ⁇ ⁇ ((! Weight capacity ⁇ , preferably 0.1 to 7 Weight Z volume% is blended. Water (purified water) is blended in an amount of 3 to 25 wt%, preferably 5 to 15 wt / vol%.
- n-butane is used because of its physical properties such as boiling point and specific gravity, and the purity of n-butane is preferably 80% by weight or more, more preferably. At least 90% by weight, more preferably at least 95% by weight.
- the compounding amount is from 60 to 95% by weight, and preferably from 70 to 90% by weight / volume. If the weight is less than 60% by volume, the foam is in good condition but the cracking is poor. If it exceeds 95% by weight / volume, the gas pressure is high and the state of foam is poor.
- anti-inflammatory agents antibacterial agents, hair-growing agents, anti-histamine agents, insect repellents, etc.
- active ingredients can be combined as active ingredients at 0.000i to i2 weight / volume%.
- anti-inflammatory agent steroid anti-inflammatory agents such as dexamethasone, presonizolone, dicoroconoretron, funoreosinonide, and dithiomethanone are used.
- Franzia Non-steroidal anti-inflammatory drugs such as acetate, pi-betasol 17-propionate, pernoshinonide, etc.
- salicylate Chile, salicinoleic acid, glucose, ketoprofen, ind'methasin, furnole biprophene, fenolepinac, snorepron Yun, Piroxicam, Fenchy Zach, Plano Blofen, Benza Duck, Bhu Yu Kisamak, Ibu Pro Fun Pico Norinol, Phenolbinakhetir, Loxo.Prophene, Nabroxen, Oxaprodin, AlminoProfun, Chiap Lofuun and other local stimulants, such as menthol lucca oil, camphl, noninoleic acid diphenylamide, Examples include capsaicin, benzyl nicotinate, and methyl nicotinate.
- Antibacterial agents include isopropropylmethinolefenol, chlorhexidine hydrochloride, clotrimazol, tonorenaphtate, and bifonzazo.
- Nitric acid, nitric acid nitric acid, nitric acid nitric acid nitric acid, nitric acid nitric acid nitric acid nitric acid nitric acid nitric acid nitric acid nitrate Nazol etc. are listed.
- Examples of the hair restorer include estradiol, ethyninole estradione, benzalconium chloride, pentothinolenazole and cypress.
- Kithole, benzyl nicotinate, photosensitizer, vitamin E, etc. are listed as diphenhydramine as an agent , Ketotifuun, azelastine or their salts, oxatomid, tofu- ⁇ -futo, maleic acid Examples include sodium microchromate and the like.
- Insect repellent Examples of the repellent include diet, televin oil, and pillsuloide.
- oil phase components include isopropynole lumicitrate, isopropynyl myristate, diisopropisolate sebacate, Fatty acid esters such as diethyl citrate, diisopropyl propyl adipate, glycerin caprylinoleate, and glycerin caprylate; 2—year-old dodecanol
- an oil phase component or an active ingredient and various additives are added to a pressure-resistant container, and then a valve is attached and a propellant is added. Press in.
- the pressure vessel can be manufactured by heating it to room temperature or below 60 and shaking it.
- FIG. 1 shows the results of measurement of the change in skin surface temperature of healthy adult males in Test Example 2, where A is the cracking foam preparation of Example 5, and B is a reference. The measurement results for the aerosol formulation of Example 5 are shown respectively.
- Example 1 is shown below to explain the present invention more specifically.
- Example 2 The components from 1 to 5 were mixed and heated at 50 to dissolve. Next, this solution and 6 and 7 were placed in a pressure vessel and a valve was attached. Next, 8 was press-fitted and shaken to obtain a cracking foam preparation.
- Example 2 The components from 1 to 5 were mixed and heated at 50 to dissolve. Next, this solution and 6 and 7 were placed in a pressure vessel and a valve was attached. Next, 8 was press-fitted and shaken to obtain a cracking foam preparation.
- Example 2 The components from 1 to 5 were mixed and heated at 50 to dissolve. Next, this solution and 6 and 7 were placed in a pressure vessel and a valve was attached. Next, 8 was press-fitted and shaken to obtain a cracking foam preparation.
- Example 2 The components from 1 to 5 were mixed and heated at 50 to dissolve. Next, this solution and 6 and 7 were placed in a pressure vessel and a valve was attached. Next, 8 was press-fitted and shaken to obtain a cracking foam preparation.
- Example 2 The components from 1 to 5 were mixed
- Example 3 The components from 1 to 6 were mixed and heated to 50 ° C to dissolve. Next, this solution and 7 and 8 were placed in a pressure vessel and a valve was attached. Next, 9 was press-fitted and shaken to obtain a cracking foam preparation.
- Example 3 The components from 1 to 6 were mixed and heated to 50 ° C to dissolve. Next, this solution and 7 and 8 were placed in a pressure vessel and a valve was attached. Next, 9 was press-fitted and shaken to obtain a cracking foam preparation.
- Example 3 The components from 1 to 6 were mixed and heated to 50 ° C to dissolve. Next, this solution and 7 and 8 were placed in a pressure vessel and a valve was attached. Next, 9 was press-fitted and shaken to obtain a cracking foam preparation.
- Example 3 The components from 1 to 6 were mixed and heated to 50 ° C to dissolve. Next, this solution and 7 and 8 were placed in a pressure vessel and a valve was attached. Next, 9 was press-fitted and shaken to obtain a cracking foam preparation.
- Example 7 The components (1) to (4) were mixed and heated to 50 ° C to dissolve them. Then, the solution (4) to (5) was placed in a pressure vessel and a valve was attached. Next, 10 was injected and shaken to obtain a cracking mousse formulation containing an anti-inflammatory and analgesic agent.
- Example 7 The components (1) to (4) were mixed and heated to 50 ° C to dissolve them. Then, the solution (4) to (5) was placed in a pressure vessel and a valve was attached. Next, 10 was injected and shaken to obtain a cracking mousse formulation containing an anti-inflammatory and analgesic agent. Example 7
- Example 13 The components from 1 to 7 were mixed and heated to 50 ° C to dissolve. Separately, put 9 into 10 and ⁇ ⁇ and stirred to swell, and put this and the previous oil phase and ⁇ into a pressure vessel. I attached the valve. Next, 12 was press-injected and shaken to obtain a cracking film preparation containing an anti-inflammatory analgesic.
- Example 13 The components from 1 to 7 were mixed and heated to 50 ° C to dissolve. Separately, put 9 into 10 and ⁇ ⁇ and stirred to swell, and put this and the previous oil phase and ⁇ into a pressure vessel. I attached the valve. Next, 12 was press-injected and shaken to obtain a cracking film preparation containing an anti-inflammatory analgesic. Example 13
- Example 15 The components (1) to (4) were mixed and dissolved by heating to 50 ° C. Then, this solution and (1) to (5) were placed in a pressure vessel and a valve was attached. Next, 12 was press-fitted and shaken to obtain a cracking foam preparation containing an antibacterial agent.
- Example 15 The components (1) to (4) were mixed and dissolved by heating to 50 ° C. Then, this solution and (1) to (5) were placed in a pressure vessel and a valve was attached. Next, 12 was press-fitted and shaken to obtain a cracking foam preparation containing an antibacterial agent.
- Example 15 The components (1) to (4) were mixed and dissolved by heating to 50 ° C. Then, this solution and (1) to (5) were placed in a pressure vessel and a valve was attached. Next, 12 was press-fitted and shaken to obtain a cracking foam preparation containing an antibacterial agent.
- Example 15 The components (1) to (4) were mixed and dissolved by heating to 50 ° C. Then, this solution and (1) to (5) were placed in
- Example 16 The components (1) to (4) were mixed and dissolved by heating at 50. Then, this solution and (1) to (4) were placed in a pressure vessel and a valve was attached. Next, 11 was press-fitted and shaken to obtain a cracking foam formulation containing an anti-itch agent.
- Example 16 The components (1) to (4) were mixed and dissolved by heating at 50. Then, this solution and (1) to (4) were placed in a pressure vessel and a valve was attached. Next, 11 was press-fitted and shaken to obtain a cracking foam formulation containing an anti-itch agent.
- Example 16 The components (1) to (4) were mixed and dissolved by heating at 50. Then, this solution and (1) to (4) were placed in a pressure vessel and a valve was attached. Next, 11 was press-fitted and shaken to obtain a cracking foam formulation containing an anti-itch agent.
- the components from 1 to 6 were mixed and heated to 5 (dissolved by heating in TC. Separately, put 7 into 8 and 9 and agitate to swell. Put this and the previous oil phase into a pressure vessel and open the valve. Next, 10 was injected and shaken to obtain an aerosol formulation containing an anti-inflammatory analgesic.
- Example 5 The cracking foam preparation of Example 5 and the aerosol preparation of Reference Example 5 were placed on a forearm of a healthy adult male for 2 seconds from a paper with a circle of about 5 cra in diameter. Sprayed. Immediately after spraying, the temperature change of the skin surface was measured using a thermograph. The results are shown in Fig. 1.
- the cracking foam formulation of Example 5 has a higher instantaneous skin cooling effect than the aerosol formulation of Reference Example 5 and the anti-inflammatory effect. Excellent as an analgesic
- the foamed aerosol preparation of the present invention has n-butane as a propellant. Despite the use of evening gas, it has very good bubbling and excellent cracking sound during rubbing. In addition, since n-butane gas is used instead of the conventional flon gas used as a propellant, there is no destruction of the ozone layer and from the viewpoint of environmental conservation, Especially useful.
- the foamed aerosol formulation containing the anti-inflammatory analgesic of the present invention contains a large amount of gas and the gas is efficiently incorporated into the foam. Compared to aerosol preparations, they have a higher cooling effect when sprayed and are superior in anti-inflammatory and analgesic effects.
- the foam aerosol and pill preparations of the present invention can be used for cosmetics, quasi-drugs, It can be applied to pharmaceuticals, etc., and is an industrially useful formulation.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Dispersion Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/689,067 US5352437A (en) | 1989-07-28 | 1990-07-23 | Foamable aerosol preparation |
DE69020900T DE69020900T2 (de) | 1989-07-28 | 1990-07-23 | Schaumaerosolzusammensetzung. |
EP90910913A EP0484530B1 (en) | 1989-07-28 | 1990-07-23 | Foamed aerosol preparation |
KR1019920700168A KR950002879B1 (ko) | 1989-07-28 | 1990-07-23 | 거품상 에어로솔제제 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1/197674 | 1989-07-28 | ||
JP19767489 | 1989-07-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991001712A1 true WO1991001712A1 (fr) | 1991-02-21 |
Family
ID=16378453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1990/000944 WO1991001712A1 (fr) | 1989-07-28 | 1990-07-23 | Preparation pour aerosol en mousse |
Country Status (10)
Country | Link |
---|---|
US (1) | US5352437A (ja) |
EP (1) | EP0484530B1 (ja) |
JP (1) | JP2741105B2 (ja) |
KR (1) | KR950002879B1 (ja) |
AT (1) | ATE124860T1 (ja) |
AU (1) | AU629670B2 (ja) |
CA (1) | CA2042583C (ja) |
DE (1) | DE69020900T2 (ja) |
DK (1) | DK0484530T3 (ja) |
WO (1) | WO1991001712A1 (ja) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0578241A (ja) * | 1991-03-06 | 1993-03-30 | Dompe Farmaceut Spa | ケトプロフエンリジン塩を含む局所用親水性医薬組成物 |
JPH06234628A (ja) * | 1993-02-09 | 1994-08-23 | Kao Corp | 皮膚外用剤 |
JPH07330540A (ja) * | 1994-06-09 | 1995-12-19 | Osaka Zosenjo:Kk | スキンケア用エアゾール組成物 |
JPH09169640A (ja) * | 1995-10-18 | 1997-06-30 | Sekisui Chem Co Ltd | 皮膚疾患治療用外用剤 |
GB2338649A (en) * | 1998-06-25 | 1999-12-29 | Brian Francis Hawtin | Nasal antiseptic compositions |
JP2002524490A (ja) * | 1998-09-11 | 2002-08-06 | ソルテック リサーチ プロプライアタリィ リミティド | ムースの組成 |
JP2003119109A (ja) * | 2001-10-09 | 2003-04-23 | T Hasegawa Co Ltd | エアゾール組成物 |
JP4871728B2 (ja) * | 2003-05-28 | 2012-02-08 | スティーフェル ラボラトリーズ インコーポレイテッド | 起泡性医薬組成物および障害の治療方法 |
WO2012033196A1 (ja) * | 2010-09-10 | 2012-03-15 | 株式会社ダイゾー | 発泡性エアゾール組成物 |
JP2018193333A (ja) * | 2017-05-18 | 2018-12-06 | 英昌化学工業株式会社 | クラッキングエアゾール組成物 |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE152908T1 (de) * | 1989-03-17 | 1997-05-15 | Taisho Pharmaceutical Co Ltd | Aerosolzusammensetzung zur äusserlichen verwendung |
GB2260079B (en) * | 1991-10-01 | 1995-08-09 | American Cyanamid Co | Pharmaceutical composition containing felbinac |
GB9414699D0 (en) * | 1994-07-21 | 1994-09-07 | Slagel David | Aqueous foamable composition |
GB9504265D0 (en) * | 1995-03-03 | 1995-04-19 | Medeva Plc | Corticosteroid-containing pharmaceutical composition |
DK0870497T3 (da) * | 1995-12-14 | 2004-05-24 | Taisho Pharmaceutical Co Ltd | Aerosolpræparat |
FR2745716B1 (fr) * | 1996-03-07 | 1998-04-17 | Oreal | Emulsions huile-dans-eau moussantes pressurisables ultrafines |
JPH10120560A (ja) * | 1996-08-26 | 1998-05-12 | Sankyo Co Ltd | ロキソプロフェン含有外用製剤 |
US6214318B1 (en) | 1997-10-02 | 2001-04-10 | Oms Holdings Llc | Aerosol ointment compositions for topical use |
AUPO983897A0 (en) | 1997-10-17 | 1997-11-06 | Soltec Research Pty Ltd | Topical antifungal composition |
US6146620A (en) * | 1997-12-09 | 2000-11-14 | Janowski; Leonard J. | Shaving compositions useful in altering the growth of male beard hair |
FR2761600B1 (fr) * | 1998-06-19 | 2000-03-31 | Oreal | Composition moussante pour le lavage et le traitement des cheveux et/ou du cuir chevelu a base d'un principe actif, d'un tensioactif anionique, d'un tensioactif amphotere et d'un agent propenetrant |
US8263580B2 (en) | 1998-09-11 | 2012-09-11 | Stiefel Research Australia Pty Ltd | Vitamin formulation |
US6389455B1 (en) * | 1998-09-22 | 2002-05-14 | Richard C. Fuisz | Method and apparatus for bouncing electronic messages |
US6315949B1 (en) | 1999-12-30 | 2001-11-13 | Robert Carmello | Composition for carpet and room deodorizer and method of delivering the composition |
US6808701B2 (en) * | 2000-03-21 | 2004-10-26 | Johnson & Johnson Consumer Companies, Inc. | Conditioning compositions |
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
AUPR048600A0 (en) * | 2000-10-02 | 2000-10-26 | Soltec Research Pty Ltd | Pharmaceutical vehicle |
US20030206872A1 (en) * | 2001-05-18 | 2003-11-06 | Classified Cosmetics | Sprayable beautifying composition |
US6589541B2 (en) | 2001-05-18 | 2003-07-08 | Classified Cosmetics, Inc. | Sprayable beautifying composition |
GB0118689D0 (en) * | 2001-08-01 | 2001-09-19 | Psimedica Ltd | Pharmaceutical formulation |
IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
AU2003279493B2 (en) | 2002-10-25 | 2009-08-20 | Foamix Pharmaceuticals Ltd. | Cosmetic and pharmaceutical foam |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
AR042906A1 (es) * | 2003-01-24 | 2005-07-06 | Connetics Australia Pty Ltd | Espuma de fosfato de clindamicina sensible a la temperatura y metodo de tratamiento de acne que la utiliza |
US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
US20050042182A1 (en) * | 2003-08-13 | 2005-02-24 | Moshe Arkin | Topical compositions of urea |
US20050037040A1 (en) * | 2003-08-13 | 2005-02-17 | Moshe Arkin | Topical compositions of urea and ammonium lactate |
US20050036953A1 (en) * | 2003-08-13 | 2005-02-17 | Moshe Arkin | Topical compositions of ammonium lactate |
US20050042268A1 (en) * | 2003-07-16 | 2005-02-24 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US20050069499A1 (en) * | 2003-09-25 | 2005-03-31 | Moshe Arkin | Foamable compositions, processes of preparing same and uses thereof |
BRPI0414883A (pt) | 2003-09-29 | 2006-12-12 | Ethena Healthcare Inc | composição, concentrado de composição, e, composições alcoólicas desinfetante e semelhante a gel |
US20060034779A1 (en) * | 2004-08-02 | 2006-02-16 | Agis Industries (1983) Ltd. | Foamable compositions containing vitamin D3 analogues, processes for preparing same and methods of treatment utilizng same |
US20060057075A1 (en) * | 2004-08-02 | 2006-03-16 | Moshe Arkin | Pharmaceutical and cosmeceutical wash-off mousse shampoo compositions, processes for preparing the same and uses thereof |
US7704522B2 (en) * | 2004-09-08 | 2010-04-27 | Clyde Morgan | Topical medicament |
US7114996B2 (en) * | 2004-09-08 | 2006-10-03 | Advanced Interconnections Corporation | Double-pogo converter socket terminal |
DE102004062775A1 (de) * | 2004-12-21 | 2006-06-29 | Stockhausen Gmbh | Alkoholischer Pumpschaum |
KR101455554B1 (ko) | 2005-03-07 | 2014-10-27 | 디이비 월드와이드 헬스케어 인코포레이티드 | 실리콘-기제 계면활성제를 갖는 고함량 알코올 폼 형성 조성물 |
JP2008540508A (ja) | 2005-05-09 | 2008-11-20 | フォーミックス エルティーディー. | 起泡性ビヒクル及びその医薬組成物 |
AU2006253913B2 (en) | 2005-06-01 | 2010-09-16 | Mayne Pharma Llc | Vitamin formulation |
US7651990B2 (en) * | 2005-06-13 | 2010-01-26 | 3M Innovative Properties Company | Foamable alcohol compositions comprising alcohol and a silicone surfactant, systems and methods of use |
US7307053B2 (en) * | 2005-12-20 | 2007-12-11 | S.C. Johnson & Son, Inc. | Combination air sanitizer, soft surface deodorizer/sanitizer and hard surface disinfectant |
ITPD20060092A1 (it) | 2006-03-17 | 2007-09-18 | Stefano Sala | Prodotto cosmetico o farmaceutico per uso topico |
BRPI0709674A2 (pt) | 2006-03-31 | 2011-12-06 | Stiefel Res Australia Pty Ltd | gel de suspensão espumante |
US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US8846651B2 (en) * | 2007-03-01 | 2014-09-30 | Takasago International Corporation | Lipid composition having excellent shape retention property and product |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
WO2009069006A2 (en) | 2007-11-30 | 2009-06-04 | Foamix Ltd. | Foam containing benzoyl peroxide |
WO2010041141A2 (en) | 2008-10-07 | 2010-04-15 | Foamix Ltd. | Oil-based foamable carriers and formulations |
WO2009072007A2 (en) | 2007-12-07 | 2009-06-11 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
WO2009087578A2 (en) * | 2008-01-08 | 2009-07-16 | Foamix Ltd. | Sensation modifying topical composition foam |
WO2009090558A2 (en) | 2008-01-14 | 2009-07-23 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
CN102341123A (zh) * | 2009-03-11 | 2012-02-01 | 兴和株式会社 | 含有镇痛-抗炎症剂的外用剂 |
US20120087872A1 (en) | 2009-04-28 | 2012-04-12 | Foamix Ltd. | Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof |
CA2769625C (en) | 2009-07-29 | 2017-04-11 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
WO2011013008A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
CN102686205A (zh) | 2009-10-02 | 2012-09-19 | 弗艾米克斯有限公司 | 局部四环素组合物 |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US9402968B2 (en) | 2012-07-11 | 2016-08-02 | Mercy Medical Research Institute, Inc. | Colorectal delivery device |
US10806769B2 (en) | 2016-03-31 | 2020-10-20 | Gojo Industries, Inc. | Antimicrobial peptide stimulating cleansing composition |
JP2019510036A (ja) | 2016-03-31 | 2019-04-11 | ゴジョ・インダストリーズ・インコーポレイテッド | プロバイオティクス/プレバイオティクス有効成分を含む清浄剤組成物 |
MX2017011630A (es) | 2016-09-08 | 2018-09-25 | Foamix Pharmaceuticals Ltd | Composiciones y metodos para tratar rosacea y acne. |
AU2017365019A1 (en) | 2016-11-23 | 2019-07-11 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6254784A (ja) * | 1985-09-04 | 1987-03-10 | Osaka Eyazoole Kogyo Kk | エアゾ−ル組成物 |
JPS63108091A (ja) * | 1986-10-24 | 1988-05-12 | Lion Corp | エアゾ−ル組成物 |
JPS63141910A (ja) * | 1986-12-04 | 1988-06-14 | Osaka Eyazoole Kogyo Kk | ボデイコロン用エアゾ−ル組成物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1314370A (en) * | 1970-02-09 | 1971-09-30 | Alberto-Culver Company | Gas-releasable and foamable compositions |
US3705855A (en) * | 1970-07-24 | 1972-12-12 | Colgate Palmolive Co | Reversible-emulsion aerosol system |
US4574052A (en) * | 1984-05-31 | 1986-03-04 | Richardson-Vicks Inc. | Crackling aerosol foam |
US4652389A (en) * | 1984-12-14 | 1987-03-24 | The Clorox Company | Carpet cleaner |
US5223244A (en) * | 1988-06-20 | 1993-06-29 | Shiseido Company, Ltd. | Aerosol composition |
ES2052879T3 (es) * | 1988-12-27 | 1994-07-16 | Osaka Shipbuilding | Composicion de aerosol. |
JP3172027B2 (ja) * | 1994-02-14 | 2001-06-04 | 株式会社コガネイ | 自動交換装置 |
-
1990
- 1990-07-23 DK DK90910913.4T patent/DK0484530T3/da active
- 1990-07-23 WO PCT/JP1990/000944 patent/WO1991001712A1/ja not_active Application Discontinuation
- 1990-07-23 EP EP90910913A patent/EP0484530B1/en not_active Revoked
- 1990-07-23 CA CA002042583A patent/CA2042583C/en not_active Expired - Fee Related
- 1990-07-23 AU AU60331/90A patent/AU629670B2/en not_active Ceased
- 1990-07-23 DE DE69020900T patent/DE69020900T2/de not_active Revoked
- 1990-07-23 AT AT90910913T patent/ATE124860T1/de not_active IP Right Cessation
- 1990-07-23 US US07/689,067 patent/US5352437A/en not_active Expired - Lifetime
- 1990-07-23 JP JP2510213A patent/JP2741105B2/ja not_active Expired - Lifetime
- 1990-07-23 KR KR1019920700168A patent/KR950002879B1/ko not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6254784A (ja) * | 1985-09-04 | 1987-03-10 | Osaka Eyazoole Kogyo Kk | エアゾ−ル組成物 |
JPS63108091A (ja) * | 1986-10-24 | 1988-05-12 | Lion Corp | エアゾ−ル組成物 |
JPS63141910A (ja) * | 1986-12-04 | 1988-06-14 | Osaka Eyazoole Kogyo Kk | ボデイコロン用エアゾ−ル組成物 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0578241A (ja) * | 1991-03-06 | 1993-03-30 | Dompe Farmaceut Spa | ケトプロフエンリジン塩を含む局所用親水性医薬組成物 |
JPH06234628A (ja) * | 1993-02-09 | 1994-08-23 | Kao Corp | 皮膚外用剤 |
JPH07330540A (ja) * | 1994-06-09 | 1995-12-19 | Osaka Zosenjo:Kk | スキンケア用エアゾール組成物 |
JPH09169640A (ja) * | 1995-10-18 | 1997-06-30 | Sekisui Chem Co Ltd | 皮膚疾患治療用外用剤 |
GB2338649A (en) * | 1998-06-25 | 1999-12-29 | Brian Francis Hawtin | Nasal antiseptic compositions |
JP2002524490A (ja) * | 1998-09-11 | 2002-08-06 | ソルテック リサーチ プロプライアタリィ リミティド | ムースの組成 |
JP2003119109A (ja) * | 2001-10-09 | 2003-04-23 | T Hasegawa Co Ltd | エアゾール組成物 |
JP4871728B2 (ja) * | 2003-05-28 | 2012-02-08 | スティーフェル ラボラトリーズ インコーポレイテッド | 起泡性医薬組成物および障害の治療方法 |
WO2012033196A1 (ja) * | 2010-09-10 | 2012-03-15 | 株式会社ダイゾー | 発泡性エアゾール組成物 |
JP2018193333A (ja) * | 2017-05-18 | 2018-12-06 | 英昌化学工業株式会社 | クラッキングエアゾール組成物 |
Also Published As
Publication number | Publication date |
---|---|
ATE124860T1 (de) | 1995-07-15 |
AU629670B2 (en) | 1992-10-08 |
CA2042583C (en) | 1995-06-20 |
DK0484530T3 (da) | 1995-08-21 |
KR920703011A (ko) | 1992-12-17 |
JP2741105B2 (ja) | 1998-04-15 |
DE69020900D1 (de) | 1995-08-17 |
US5352437A (en) | 1994-10-04 |
EP0484530A1 (en) | 1992-05-13 |
AU6033190A (en) | 1991-03-11 |
DE69020900T2 (de) | 1995-12-14 |
EP0484530B1 (en) | 1995-07-12 |
EP0484530A4 (en) | 1993-03-03 |
KR950002879B1 (ko) | 1995-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1991001712A1 (fr) | Preparation pour aerosol en mousse | |
KR0137784B1 (ko) | 외용 에어로졸제 | |
JP5937007B2 (ja) | 発泡性エアゾール組成物 | |
JP2001515022A (ja) | 泡状スキンクリーム、泡状スキンプロテクションクリームの使用及びその製造方法 | |
JP2006510651A (ja) | 安定な泡状クリーム | |
JPH01100111A (ja) | スキンケア組成物 | |
KR19980702703A (ko) | 코르티코스테로이드를 함유하는 약제학적 조성물 | |
EP1121101A1 (en) | Aerosol ointment compositions and method of manufacture | |
JP2007131539A (ja) | 冷感泡沫化粧料 | |
JPH05213734A (ja) | エアゾールマッサージ剤 | |
JP2008189644A (ja) | 自己発泡可能な皮膚清浄剤組成物 | |
TWI279438B (en) | Azeotrope-like compositions of tetrafluoroethane, pentafluoropropane and water | |
JPH04103526A (ja) | 皮膚冷却エアゾール剤 | |
JPH06305934A (ja) | エアゾール型化粧料 | |
JP5986394B2 (ja) | 泡沫形成エアゾール組成物 | |
JP2000297008A (ja) | 発泡性化粧料 | |
JP2540536B2 (ja) | エアゾ−ル式外用塗布剤 | |
JPH0559890B2 (ja) | ||
JPH0224382A (ja) | エアゾール組成物 | |
JP6577322B2 (ja) | エタノール含有エアゾール製剤 | |
JP2805159B2 (ja) | 後発泡性パック料 | |
JPH10139658A (ja) | 皮膚冷却エアゾール剤 | |
JP2000086499A (ja) | 泡沫形成用エアゾール組成物 | |
JPH0853344A (ja) | 高固形分含有エアゾール剤の製造法 | |
JP2006298772A (ja) | 後発泡性化粧料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2042583 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1990910913 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1990910913 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1990910913 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1990910913 Country of ref document: EP |